Focused On-demand Library for Lysophosphatidic acid receptor 6

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P43657

UPID:
LPAR6_HUMAN

ALTERNATIVE NAMES:
Oleoyl-L-alpha-lysophosphatidic acid receptor; P2Y purinoceptor 5; Purinergic receptor 5; RB intron encoded G-protein coupled receptor

ALTERNATIVE UPACC:
P43657; A4FTW9; B3KVF2; F2YGU4; O15133; Q3KPF5; Q53FA0; Q5VW44; Q7Z3S0; Q7Z3S6

BACKGROUND:
The Lysophosphatidic acid receptor 6, identified by the accession number P43657, is crucial for hair growth and texture, binding specifically to oleoyl-L-alpha-lysophosphatidic acid (LPA). This receptor, also known as P2Y purinoceptor 5, plays a key role in the activation of intracellular cAMP, underscoring its importance in hair follicle maintenance and signaling.

THERAPEUTIC SIGNIFICANCE:
Dysfunction in this receptor is associated with conditions such as Woolly hair autosomal recessive 1 and Hypotrichosis 8, which involve compromised hair follicle structure and function. The exploration of Lysophosphatidic acid receptor 6's function offers a promising avenue for developing novel therapeutic approaches to treat these hair-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.